Calderone, R.G., Nimako, K., Leary, A.N., Popat, S., Kipps, E. and O’Brien, M.N. ( 2010) Use of zoledronic acid in lung cancer. J Thoracic Oncol5(Suppl 1): S99.
2.
Carbone, D.P., Seymour, L., Ding, K., Roder, H., Tsao, M. and Shepherd, F.A. ( 2010) Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib/placebo in the NCIC clinical trials groups BR.21 trial. J Thoracic Oncol5(Suppl 1): S80.
3.
Jantus, E., Cabrera, A., Sirera, R., Usó, M., Gallach, S., Blasco, A. et al. (2010) Molecular expression of angiogenic markers in early-stage NSCLC: evaluation of the prognostic role. J Thoracic Oncol5(Suppl 1): S67.
4.
Mornex, F., Tourani, J.M., Wautot, V., Chouaki, N., Thareau Vaury, A., Bourayou, N. et al. (2010) Pemetrexed (PEM) and cisplatin (CIS) in concurrent combination with high dose of thoracic radiation (RT), after induction chemotherapy (CT), in patients (PTS) with locally advanced nonsmall cell lung cancer (NSCLC): a phase I study. J Thoracic Oncol5(Suppl 1): S73.
5.
Otsuka, S., Klimowicz, A., Kopciuk, K., Petrillo, S., Stolte, E., Konno, M. et al. (2010) CXCR4 over-expression by immunohistochemistry (IHC) heralds poor outcome in metastatic NSCLC. J Thoracic Oncol5(Suppl 1): S39.
6.
Pirker, R., Herth, F.J.F., Kerr, K., Filipits, M., Grunenwald, D., Popper, H. et al. (2010) EGFR mutation testing in non-small-cell lung cancer (NSCLC): clinical recommendations form the EGFR workshop group. J Thoracic Oncol5(Suppl 1): S79.
